Luo Shi, Li Peiwen, Li Sha, Du Zhengwu, Hu Xun, Fu Yao, Zhang Zhirong
Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University , Chengdu 610041, China.
Mol Pharm. 2017 May 1;14(5):1771-1781. doi: 10.1021/acs.molpharmaceut.7b00028. Epub 2017 Mar 27.
Acute pancreatitis (AP) is a sudden inflammation of the pancreas with high mortality rate worldwide. As a severe complication to AP, acute lung injury has been the major cause of death among patients with AP. Poor penetration across the blood pancreas barrier (BPB) and insufficient drug accumulation at the target site often result in poor therapeutic outcome. Our previous work successfully demonstrated a dual-specific targeting strategy to pancreas and lung using a phenolic propanediamine moiety. Inspired by this, a simplified ligand structure, N,N-dimethyl tertiary amino group, was covalently conjugated to celastrol (CLT) to afford tertiary amino conjugates via either an ester (CP) or an amide linkage (CTA). With sufficient plasma stability, CTA was subjected to the following studies. Compared to CLT, CTA exhibited excellent cellular uptake efficiency in both rat pancreatic acinar cell line (AR42J) and human pulmonary alveolar epithelial cell line (A549). Organic cation transporters were proven to be responsible for this active transport process. Given systemically, CTA specifically distributed to pancreases and lungs in rats thus resulting in a 2.59-fold and 3.31-fold increase in tissue-specific accumulation as compared to CLT. After CTA treatment, tissue lesions were greatly alleviated and the levels of proinflammatory cytokines were downregulated in rats with sodium taurocholate induced AP. Furthermore, CTA demonstrated marginal adverse effect against major organs with reduced cardiac toxicity compared to CLT. Together, tertiary amine mediated dual pancreas- and lung-targeting therapy represents an efficient and safe strategy for AP management.
急性胰腺炎(AP)是胰腺的一种突发性炎症,在全球范围内死亡率很高。作为AP的一种严重并发症,急性肺损伤一直是AP患者的主要死因。药物穿过血胰屏障(BPB)的渗透性差以及在靶部位的药物蓄积不足,常常导致治疗效果不佳。我们之前的工作成功证明了一种使用酚丙二胺部分对胰腺和肺进行双特异性靶向的策略。受此启发,一种简化的配体结构,即N,N - 二甲基叔氨基,通过酯键(CP)或酰胺键(CTA)与雷公藤红素(CLT)共价偶联,得到叔氨基共轭物。由于具有足够的血浆稳定性,CTA进行了以下研究。与CLT相比,CTA在大鼠胰腺腺泡细胞系(AR42J)和人肺泡上皮细胞系(A549)中均表现出优异的细胞摄取效率。有机阳离子转运体被证明负责这种主动转运过程。经全身给药后,CTA在大鼠体内特异性分布于胰腺和肺,因此与CLT相比,组织特异性蓄积增加了2.59倍和3.31倍。CTA治疗后,牛磺胆酸钠诱导的AP大鼠的组织损伤得到极大缓解,促炎细胞因子水平下调。此外,与CLT相比,CTA对主要器官的不良反应较小,心脏毒性降低。总之,叔胺介导的双胰腺和肺靶向治疗是一种有效且安全的AP治疗策略。